 |
|
|
| |
Evaluating utilization and management of comedications with potential for drug-drug interactions among patients with chronic hepatitis C initiating treatment with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
|
| |
| |
EASL 2023 june 21-24 vienna
Stuart Gordon1, Andrea Steffens2, Laura Weber2, Kimberly McNiff2, Alon Yehoshua3
1Henry Ford Hospital, Detroit, MI, USA; 2HEOR, Optum Life Science, Eden Prairie, MN, USA 3HEOR Liver Disease, Gilead Sciences, Foster City, CA, USA
|
| |
|
|
|
|
|
